Site navigation

Navigation

Psoriatic arthritis (moderate to severe) - adalimumab

Adalimumab for the treatment of psoriatic arthritis

Summary

Adalimumab should be offered as an option for treating adults with active and progressive psoriatic arthritis when: the person has arthritis with three or more tender joints and three or more swollen joints, and at least two other disease-modifying anti-rheumatic drugs (DMARDs), given on their ...

Read the complete summary


Guidance documents

Implementing this guidance

Other information

About this guidance

Technology appraisals TA125

Issued: August 2007

How this guidance was produced

See also:

See this guidance in practice:

Order printed copies of this guidance